Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lisdexamfetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lisdexamfetamine SCHEMBL158949 | 1.00 | MMP2 (0.64) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL7919487 | 1.00 | MMP2 (0.64) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL25674417 | 1.00 | MMP2 (0.64) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL31439237 | 1.00 | MMP2 (0.64) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL12947679 | 1.00 | MMP2 (0.64) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL31173641 | 1.00 | MMP2 (0.64) | MMP2NPC1RAB9ALTA4HLMNA | |
| SCHEMBL21657924 | 0.99 | MMP2 (0.63) | MMP2NPC1RAB9ALTA4HLMNA | |
| SCHEMBL1844896 | 0.96 | MMP2 (0.59) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL970534 | 0.95 | MMP2 (0.59) | MMP2NPC1RAB9ALTA4HLMNA | |
| Lisdexamfetamine SCHEMBL678421 | 0.95 | MMP2 (0.59) | MMP2NPC1RAB9ALTA4HLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171395-A1 | PROCESS FOR THE PREPARATION OF AMPHETAMINE AND DERIVATIVES THEREOF | GRANULES INDIA LIMITED (IN) | 2025-05-29 | — | — | US | disclosed |
| EP-4279062-A1 | LIQUID COMPOSITION AND ITS USE, TREATMENT METHOD AND KIT | EMS S.A. (BR) | 2023-11-22 | — | — | EP | disclosed |
| EP-4122914-B1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI PHARMTECH INC (TW) | 2023-08-16 | — | — | EP | disclosed |
| EP-4215517-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI Pharmtech Inc. (CN) | 2023-07-26 | — | — | EP | disclosed |
| EP-4122914-A1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI Pharmtech Inc. (CN) | 2023-01-25 | — | — | EP | disclosed |
| CN-111698983-B | Compound oral pharmaceutical dosage form comprising fixed doses of an ADHD non-stimulant and an ADHD stimulant | 南京三迭纪医药科技有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-111698983-A | Compound oral pharmaceutical dosage form comprising fixed doses of an ADHD non-stimulant and an ADHD stimulant | 南京三迭纪医药科技有限公司 | 2020-09-22 | — | — | CN | disclosed |
| EP-3459538-B1 | CRYSTALLINE SALTS OF A DEXTROAMPHETAMINE PRODRUG | SANDOZ AG (CH) | 2020-05-06 | — | — | EP | disclosed |
| EP-3459538-A1 | CRYSTALLINE SALTS OF A DEXTROAMPHETAMINE PRODRUG | Sandoz AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| EP-1644019-B2 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | SHIRE LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-7105486-B2 | Administering L-lysine-d-amphetamine; attention deficit hyperactivity disorder; decreasing the bioavailability of amphetamine by intravenous or intranasal administration, further limiting their abuse liability. | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1675555-A2 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF OVERDOSE OR ABUSE | New River Pharmaceuticals Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2006052880-A2 | SYNERGISTIC EFFECTS OF COMBINED ADMINISTRATION OF MIRTAZAPINE AND A STIMULANT COMPOUND | NEW RIVER PHARMACEUTICALS INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100136-A1 | Synergistic effects of combined administration of mirtazapine and a stimulant compound | SHIRE LLC | 2006-05-11 | — | — | US | disclosed |
| EP-1644019-A1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | New River Pharmaceuticals Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050176646-A1 | Covalently bonding a narcotic to a single amino acid or an oligopeptide of 15 or fewer amino acids such that the narcotic does not release into a patient's bloodstream at levels that give rise to a euphoric or overdose level | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005032474-A2 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF OVERDOSE OR ABUSE | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050054561-A1 | Abuse-resistant amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005000334-A1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | NEW RIVER PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054561-A1 | Abuse-resistant amphetamine compounds | COMT, CYP3A5, SLC6A2 | MMP2 2665/4885NPC1 73/4885RAB9A 3013/4885 |
| US-20050038121-A1 | Abuse resistant lysine amphetamine compounds | COMT, KDM6B, KDM5B | MMP2 2188/4885NPC1 137/4885RAB9A 2367/4885 |
| US-20050176646-A1 | Covalently bonding a narcotic to a single amino acid or an oligopeptide of 15 or fewer amino acids such that the narcotic does not release into a patient's bloodstream at levels that give rise to a euphoric or overdose level | DNPEP, OGFR, OPRL1 | MMP2 1028/4885NPC1 3556/4885RAB9A 2367/4885 |
| US-20250171395-A1 | PROCESS FOR THE PREPARATION OF AMPHETAMINE AND DERIVATIVES THEREOF | COMT, DDT, DBH | MMP2 3841/4885NPC1 3080/4885RAB9A 1893/4885 |
| US-20060100136-A1 | Synergistic effects of combined administration of mirtazapine and a stimulant compound | SLC6A4, HTR5A, HTR4 | MMP2 1757/4885NPC1 738/4885RAB9A 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.